共 160 条
[1]
Weinstein RS(2011)Clinical practice. Glucocorticoid-induced bone disease N Engl J Med 365 62-70
[2]
Angeli A(2006)High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study Bone 39 253-259
[3]
Guglielmi G(2003)Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy Arthritis Rheum 48 3224-3229
[4]
Dovio A(2010)Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid Gend Med 7 218-229
[5]
Capelli G(2017)The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease Arch Osteoporos 12 44-299
[6]
de Feo D(1998)Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group N Engl J Med 339 292-2318
[7]
Giannini S(1999)Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 42 2309-2039
[8]
Giorgino R(2007)Teriparatide or alendronate in glucocorticoid-induced osteoporosis N Engl J Med 357 2028-1998
[9]
Moro L(2016)Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 27 1989-E648
[10]
Giustina A(2013)Impact of initial conservative treatment interventions on the outcomes of patients with osteoporotic vertebral fractures Spine 38 E641-2077